We study innate and adaptive immunity to #viruses and #cancer. #COVID19 #immunology #vaccines @HHMINEWS @YaleIBIO @YaleMed @YaleEMD @YaleSPH.
How do the various mutations within the SARS-CoV-2 variants impact vaccine-induced immunity? The amazing @carolilucas @VogelsChantal @InciYildirim11 led this study with with help from others to tackle this question - using 18 CoV-2 variants. (1/n)
The study was designed to measure antibody and T cell immunity from people who were previously infected or not infected with SARS-CoV-2, before and after the 1st and 2nd doses of mRNA vaccines. Amazing effort by @InciYildirim11 @SaadOmer3 (2/n) pic.twitter.com/tyqr1Z2zCY
Antibodies to the ancestral S1 and RBD were induced in both prev. infected and uninfected vaccinees. S/S1/RBD-specific IgG levels in response to vaccination were significantly higher in the previously infected compared to uninfected, as reported by others. (3/n) pic.twitter.com/610vLDgcQR
Next, neutralization activity of antibodies induced by the mRNA vaccines was measured through 50% plaque-reduction neutralization (PRNT50). Despite faster and higher NAb responses in previously infected, similar NAb levels were achieved after 2nd dose in both groups. (4/n) pic.twitter.com/aPq8mE5Maz
Notice that even though every vaccinated person generated anti-Spike IgG responses, 2 individuals failed to induce neutralizing Abs even after the 2 shots. We don’t know the underlying cause yet. (5/n)
Next we examined CD4 and CD8 T cell responses to spike and nucleocapsid proteins. mRNA vaccines induced robust activation of CD4 T cells in both previously infected and uninfected vaccinees against ancestral and P.1 spike. (6/n) pic.twitter.com/QrW6mRo4In
In contrast, we found reduced CD8 T cell responses to the P.1 variant spike antigen compared to ancestral spike. This may be related to the various mutations in P.1 spike protein. Mutations are discussed below. (7/n) pic.twitter.com/5RSTaRJVH0
Great thread describing our most recent study on vaccine-induced immunity against SARS-CoV-2 variants!👇 So grateful for the amazing collaboration with @carolilucas @VirusesImmunity @NathanGrubaugh @InciYildirim11 @SaadOmer3 and the rest of the team!🙌 twitter.com/VirusesImmunit…
Dr. Angela Rasmussen
Mon Jul 19
Wow—really fantastic work by a collaborative team at Yale led by @VirusesImmunity, systematically characterizing immune effects of various variants’ mutations/combinations of mutations. twitter.com/VirusesImmunit…
Some further musings on our work with @carolilucas, @VogelsChantal, @InciYildirim11, @SaadOmer3,
& @VirusesImmunity. I'll start by nerding 🤓 out on some of the genetics and end with some thoughts 🤔 about vaccination strategies (/gasp). (1/22)
WOW!!! You have to read this incredible thread from @VirusesImmunity describing her new study on the response to #SARS_CoV_2 variants in vaccinated people.
physician-scientist, author, editor
Neutralization capacity (antibody and T-cell response) for Prior covid + vaccination > 2-doses vaccine across major variants
"pointing to vaccine boosters as a relevant future strategy"
by @carolilucas @NathanGrubaugh @VirusesImmunity @YaleIBIO @YaleMed pic.twitter.com/1JOfEqXTY9
So what does this all mean for levels of protection and vaccination strategies? Our preprint, and subsequent twitter threads, have initiated a lot of discussion/speculation on this front. (15/22)
First, our work does NOT imply that natural infection is better than vaccination in terms of neutralization, as some commenters have suggested. And we are certainly not suggesting that people try to get infected as a way to boost their NAbs. (16/22)
What we are saying is that IF NAb titers are directly correlated with protection (which there is probably more to it than that), than a boosted immune response could help increase protection against the variants on the far end of the spectrum (e.g. Beta, Gamma). (17/22) pic.twitter.com/Pcym6LVGwC